A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

INTRODUCTION:Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with...

Full description

Bibliographic Details
Main Authors:	Stuart McPherson, Nina Wilkinson, Dina Tiniakos, Jennifer Wilkinson, Alastair D Burt, Elaine McColl, Deborah D Stocken, Nick Steen, Jane Barnes, Nicola Goudie, Stephen Stewart, Yvonne Bury, Derek Mann, Quentin M Anstee, Christopher P Day
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5395178?pdf=render

Similar Items

Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes.
by: Shoko Ishizu-Higashi, et al.
Published: (2014-01-01)

Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats
by: Arian Amirkhosravi, et al.
Published: (2024-04-01)

The Effectivity of Losartan Tablet for Decreasing Fibrotic Tissue Formation in Gastrocnemius Muscle Injury Grade I of Rabbits
by: Boby Harul Priono, et al.
Published: (2019-04-01)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
by: Quentin M Anstee, et al.
Published: (2021-04-01)

Orlistat for overweight subjects with nonalcoholic steatohepatitis.
by: Dowman, J, et al.
Published: (2009)

Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis
by: Kyounghee Min, et al.
Published: (2024-04-01)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
by: Kawaratani Hideto, et al.
Published: (2009-05-01)

Diagnostic accuracy of exhaled nitric oxide for the non-invasive identification of patients with fibrotic metabolic dysfunction-associated steatohepatitis
by: Huai Zhang, et al.
Published: (2024-12-01)

Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations
by: Daniel Heinrichs, et al.
Published: (2021-01-01)

Efficacy of Dietary Lipid Control in Healing High-Fat and High-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats.
by: Hazuki Tamada, et al.
Published: (2016-01-01)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
by: James Twiss, et al.
Published: (2023-07-01)

Sex differences in predicting dyslipidemia using polygenic risk score with fatty liver index and fibrotic nonalcoholic steatohepatitis index
by: Sei Kim, et al.
Published: (2025-03-01)

The feasibility of electrochemical ammonia synthesis in molten LiCl-KCl eutectics
by: McPherson, I, et al.
Published: (2019)

Losartan therapy in gout patients
by: A. I. Ilyina, et al.
Published: (2008-04-01)

Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling
by: Ognoon Mungunsukh, et al.
Published: (2014-11-01)

Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan
by: Antônio Carlos Avanza Jr, et al.
Published: (2000-02-01)

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
by: Yet H. Khor, et al.
Published: (2020-08-01)

Novel Anti-fibrotic Therapies
by: Benita L. McVicker, et al.
Published: (2017-05-01)

Embedding assessment of liver fibrosis into routine diabetic review in primary care
by: Dina Mansour, et al.
Published: (2021-08-01)

The effects of losartan and diazepam on emotional processing
by: Thoroddsen, TA
Published: (2021)

Comparison of the GPVI inhibitors losartan and honokiol
by: Marie-Blanche Onselaer, et al.
Published: (2020-02-01)

Spectrophotometric Determination of Losartan Potassium in Tablets
by: Arianne Diane A. Aniñon, et al.
Published: (2014-06-01)

Losartan Enhances the Success of Myoblast Transplantation
by: Raouia Fakhfakh, et al.
Published: (2012-02-01)

Determination of Losartan and Losartan Carboxylic acid in Human Plasma by New HPLC Method with Fluorescence Detection for Pharmacokinetics Studies
by: Ahmed Abbas Hussein
Published: (2014-12-01)

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
by: Fini Massimo, et al.
Published: (2005-05-01)

Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study
by: Jamie O'Hara, et al.
Published: (2020-10-01)

The role of angiotensin receptor blocker (losartan) on decreasing fibrotic process of corpora cavernosa in priapism model of wistar rats [version 3; peer review: 1 approved, 2 approved with reservations]
by: Rangga Adhazi Ksatriapraja, et al.
Published: (2024-02-01)

The role of angiotensin receptor blocker (losartan) on decreasing fibrotic process of corpora cavernosa in priapism model of wistar rats [version 2; peer review: 1 approved, 2 approved with reservations]
by: Rangga Adhazi Ksatriapraja, et al.
Published: (2023-05-01)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
by: Laura Haigh, et al.
Published: (2021-10-01)

Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT
by: Patrick G Kehoe, et al.
Published: (2021-11-01)

Efficacy and safety of single-pill amlodipine/losartan versus losartan in patients with inadequately controlled hypertension after losartan treatment: a multicenter, double-blind, randomized phase III clinical trial
by: Shuyang Zhang, et al.
Published: (2023-06-01)

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
by: Elizabeth Ripley, et al.
Published: (2010-06-01)

Determining the Effects of Morphine, Heroin, and Losartan and the Interaction of each on Losartan in Water Homeostasis Mechanisms by the Kidney in Adult Male Rabbits
by: F Foroohi, et al.
Published: (2015-04-01)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
by: Naim Alkhouri, et al.
Published: (2018-01-01)

The psychological and cognitive impact of cerebrovascular disease
by: McColl, A
Published: (2021)

The Anomalously Old Bush Stream Rock Avalanche and Its Implications for Landslide Inventories in Dynamic Landscapes
by: Samuel T. McColl
Published: (2020-04-01)

Review of Colombia: El largo camino hacia la paz después de la Guerra Civil
by: Richard McColl
Published: (2021-02-01)

Leveraging Citation Management Software (CMS) for Broad Library Impact
by: Ron McColl
Published: (2018-11-01)

Biphasic effects of losartan potassium on immobility in mice
by: Vijayapandi, P., et al.
Published: (2005)

СARDIOPROTECTION IN PATIENTS WITH HYPERTENSION – THE ROLE OF LOSARTAN
by: I. I. Chukaeva, et al.
Published: (2015-09-01)